Quintrio
Home

Stock overview

Grifois, S.A.

GRFS

Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.

Last trade $8.65
Day change -$0.085 (-0.97%)
Day range $8.59 – $8.73
Volume 399,926
Market cap $5.94B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for GRFS.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for GRFS.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

European Human Biospecimen Market Forecasts Growth from $881.8M (2025) to $1.94B by 2035, Profiling Grifols, Logical Biological & Europa Biosite

The European human biospecimen market is projected to grow at an 8.24% CAGR from $881.8 million in 2025 to $1.94 billion by 2035, driven by increasing demand for precision medicine, oncology research, and expanding biobanks. Growth is supported by rising pharmaceutical R&D spending and EU-funded initiatives, though challenges include stringent GDPR regulations, high operational costs, and variability in consent frameworks across countries.

GlobeNewswire Inc.

Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider

The global intravenous immunoglobulin (IVIG) market is projected to grow from USD 14.98 billion in 2025 to USD 30.83 billion by 2035, at a CAGR of 7.49%. Growth is driven by expanding neurological indications, increased plasma collection capacity, and rising demand for immunoglobulin-based treatments. However, plasma supply dependency and a 100% U.S. tariff on imported IVIG products implemented in October 2025 pose significant constraints. North America leads the market, while Asia-Pacific shows the fastest growth.

GlobeNewswire Inc.

[Latest] Global Botulinum Toxin in Urology Market Size/Share Worth USD 1.98 Billion by 2035 at a 6.08% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global botulinum toxin in urology market is projected to grow from USD 1.1 billion in 2025 to USD 1.98 billion by 2035, at a CAGR of 6.08%. Growth is driven by increasing prevalence of urological disorders, aging populations, preference for minimally invasive treatments, and advancements in injection techniques. OnabotulinumtoxinA (Botox) leads the market, with overactive bladder being the largest application segment.

GlobeNewswire Inc.

Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight

The hepatic encephalopathy market is projected to grow at 1.2% CAGR through 2036, valued at USD 900 million in 2025. Growth is driven by rising prevalence of chronic liver diseases, improved early diagnosis awareness, and emerging therapies from companies like Vedanta Biosciences, Yaqrit Discovery Ltd, and others. The US dominates with 60% market share, with approximately 210,000 prevalent cases across the 7MM in 2025.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily
Declared upcoming dividend $0.1686 per share
Declared
Nov 3, 2026
Ex-dividend
Dec 3, 2026
Pay date
Dec 11, 2026
Ex-dividendAmount / sharePay dateType
Jul 2, 2026$0.1058Jul 9, 2026irregular
Aug 12, 2025$0.1758Aug 20, 2025irregular
Jun 3, 2021$0.4566Jun 14, 2021recurring
Oct 30, 2020$0.2014Nov 9, 2020unknown
Dec 2, 2019$0.2219Dec 11, 2019recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jan 4, 20162-for-1forward split
Dec 11, 20121.05-for-1forward split
Jul 23, 20121-for-2reverse split
Dec 1, 201111-for-10forward split